CA2278465C - Diagnostic et traitement de defaillance myocardique - Google Patents

Diagnostic et traitement de defaillance myocardique Download PDF

Info

Publication number
CA2278465C
CA2278465C CA2278465A CA2278465A CA2278465C CA 2278465 C CA2278465 C CA 2278465C CA 2278465 A CA2278465 A CA 2278465A CA 2278465 A CA2278465 A CA 2278465A CA 2278465 C CA2278465 C CA 2278465C
Authority
CA
Canada
Prior art keywords
mhc
expression
beta
alpha
cdna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2278465A
Other languages
English (en)
Other versions
CA2278465A1 (fr
Inventor
Michael R. Bristow
Leslie A. Leinwand
Wayne Minobe
Koichi Nakao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado
Original Assignee
University of Colorado
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado filed Critical University of Colorado
Publication of CA2278465A1 publication Critical patent/CA2278465A1/fr
Application granted granted Critical
Publication of CA2278465C publication Critical patent/CA2278465C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Dental Preparations (AREA)

Abstract

L'invention concerne un procédé permettant de diagnostiquer une défaillance myocardique chez un être humain. Le procédé comporte les étapes consistant à obtenir un échantillon de tissu myocardique provenant d'un ventricule de coeur humain; quantifier l'expression de chaînes lourdes d'alpha-myosine (alpha-MHC), de chaînes lourdes de bêta-myosine (bêta-MHC), ou des deux à la fois dans l'échantillon; et déterminer par analyse statistique si l'expression d'alpha-MHC ou de bêta-MHC, ou des deux ensemble dans l'échantillon est significativement différente de leur expression dans un tissu myocardique ventriculaire humain normal.
CA2278465A 1997-01-30 1998-01-30 Diagnostic et traitement de defaillance myocardique Expired - Fee Related CA2278465C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3698797P 1997-01-30 1997-01-30
US60/036,987 1997-01-30
US3891197P 1997-02-26 1997-02-26
US60/038,911 1997-02-26
PCT/US1998/001983 WO1998033942A1 (fr) 1997-01-30 1998-01-30 Diagnostic et traitement de defaillance myocardique

Publications (2)

Publication Number Publication Date
CA2278465A1 CA2278465A1 (fr) 1998-08-06
CA2278465C true CA2278465C (fr) 2010-04-27

Family

ID=26713697

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2278465A Expired - Fee Related CA2278465C (fr) 1997-01-30 1998-01-30 Diagnostic et traitement de defaillance myocardique

Country Status (8)

Country Link
US (3) US7482331B1 (fr)
EP (1) EP1012329B1 (fr)
JP (1) JP2002501366A (fr)
KR (1) KR20000070674A (fr)
AU (1) AU6141098A (fr)
CA (1) CA2278465C (fr)
DE (1) DE69837968D1 (fr)
WO (1) WO1998033942A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040749A2 (fr) 1999-01-06 2000-07-13 Genenews Inc. Technique de detection de transcrits geniques dans le sang et leur utilisation
US7473528B2 (en) 1999-01-06 2009-01-06 Genenews Inc. Method for the detection of Chagas disease related gene transcripts in blood
US20030077611A1 (en) 2001-10-24 2003-04-24 Sention Methods and systems for dynamic gene expression profiling
US7081339B2 (en) 2002-04-12 2006-07-25 Primera Biosystems, Inc. Methods for variation detection
US7445893B2 (en) 2002-04-12 2008-11-04 Primera Biosystems, Inc. Sampling method for amplification reaction analysis
EP1563097A4 (fr) * 2002-11-21 2006-03-15 Primera Biosystems Procede et dispositif d'echantillonnage permettant d'analyser des reactions d'amplification
US7785632B2 (en) 2003-09-15 2010-08-31 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US8071134B2 (en) 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
AU2005284879B2 (en) * 2004-09-15 2011-04-14 Albany College Of Pharmacy And Health Sciences Thyroid hormone analogs for promoting angiogenesis
US20060184198A1 (en) * 2005-01-31 2006-08-17 Kms Biopsy, Llc End effector for surgical instrument, surgical instrument, and method for forming the end effector
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US20100209382A1 (en) 2005-09-16 2010-08-19 Ordway Research Institute, Inc. Polyphenol Conjugates as RGD-Binding Compounds and Methods of Use
JP2010513526A (ja) 2006-12-22 2010-04-30 シーエルエフ メディカル テクノロジー アクセラレーション プログラム インコーポレイテッド 甲状腺ホルモン類縁体、拮抗剤および製剤のためのナノ粒子及び重合体製剤ならびにその使用
WO2010120506A1 (fr) 2009-03-31 2010-10-21 Ordway Research Institute, Inc. Polythérapie anticancéreuse par cétuximab et tétrac
WO2010148007A2 (fr) 2009-06-17 2010-12-23 Ordway Research Institute, Inc. Formulations nanoparticulaires et polymères pour hormone thyroïdienne, analogues, antagonistes et formulations et utilisations de celles-ci
US9512481B2 (en) 2009-09-11 2016-12-06 The Regents Of The University Of Colorado, A Body Corporate Polymorphisms in the PDE3A gene
CA2805465A1 (fr) * 2010-06-10 2011-12-15 Myra Lipes Diagnostic d'une auto-immunite myocardique dans une maladie cardiaque
US20130121998A1 (en) * 2010-06-16 2013-05-16 Myra A. Lipes Diagnosis of Myocardial Autoimmunity in Heart Disease
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
EP3337892A2 (fr) * 2015-08-18 2018-06-27 Boston Scientific Scimed Inc. Procédés de production de cellules cardiomyocytaires
CA3026504A1 (fr) 2016-06-07 2017-12-14 Nanopharmaceuticals, Llc Polymere non clivable conjugue avec des antagonistes thyroidiens de l'integrine .alpha..nu..beta.3
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US20210380977A1 (en) * 2018-10-19 2021-12-09 The Trustees Of Indiana University Myocardial enhancer rna and methods of use
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580722A (en) 1989-07-18 1996-12-03 Oncogene Science, Inc. Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
US5219727A (en) 1989-08-21 1993-06-15 Hoffmann-Laroche Inc. Quantitation of nucleic acids using the polymerase chain reaction
GB9208000D0 (en) * 1992-04-10 1992-05-27 Univ London Quantitative viral assay
US5643765A (en) * 1993-04-06 1997-07-01 University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction

Also Published As

Publication number Publication date
EP1012329B1 (fr) 2007-06-20
KR20000070674A (ko) 2000-11-25
JP2002501366A (ja) 2002-01-15
WO1998033942A1 (fr) 1998-08-06
EP1012329A4 (fr) 2004-08-11
DE69837968D1 (de) 2007-08-02
US7049066B2 (en) 2006-05-23
US20050214835A1 (en) 2005-09-29
EP1012329A1 (fr) 2000-06-28
CA2278465A1 (fr) 1998-08-06
US7482331B1 (en) 2009-01-27
AU6141098A (en) 1998-08-25
US20030134282A1 (en) 2003-07-17

Similar Documents

Publication Publication Date Title
CA2278465C (fr) Diagnostic et traitement de defaillance myocardique
JP6448149B2 (ja) 肝線維症に関連する遺伝的多型、その検出方法および使用
Maestrini et al. A molecular defect in loricrin, the major component of the cornified cell envelope, underlies Vohwinkel's syndrome
US6709855B1 (en) Methods for detection and use of differentially expressed genes in disease states
EP1140137A2 (fr) Methodes de detection et d'utilisation de genes exprimes de fa on differentielle dans des maladies
US20030190639A1 (en) Genes involved in intestinal inflamatory diseases and use thereof
AU5810999A (en) Sequences characteristic of hypoxia-regulated gene transcription
EP1311704A2 (fr) Nouveau genes cibles pour les maladies du coeur
CN101287846A (zh) 诊断血栓栓塞病和冠心病的方法
US6475724B1 (en) Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6368794B1 (en) Detection of altered expression of genes regulating cell proliferation
US6171788B1 (en) Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
WO1998032850A9 (fr) Dispositif d'interface informatique pour ecran a plasma de type ca
Kidd et al. Regulated expression of a cell division control-related protein kinase during development
US6562574B2 (en) Association of protein kinase C zeta polymorphisms with diabetes
US6861217B1 (en) Variation in drug response related to polymorphisms in the β2-adrenergic receptor
CA2303844A1 (fr) Regulateurs de l'expression du gene ucp3
Marin‐Garcia et al. Specific mitochondrial DNA deletions in canine myocardial ischemia
Iwamoto et al. Identification of a single nucleotide polymorphism showing no insulin-mediated suppression of the promoter activity in the human insulin receptor substrate 2 gene
US7442509B2 (en) Detecting mutations in the feline cardiac myosin binding protein C gene associated with hypertrophic cardiomyopathy in cats
US8518644B2 (en) Method of judging inflammatory disease by using single nucleotide polymorphism
EP1118680A1 (fr) Methode de diagnostic des polymorphismes du gène humain PDH E1alpha
EP1524524A1 (fr) Méthodes de détection et d'utilisation de OSF-2 exprimés de façon différentielle pour diagnose l'hypertrophie cardiaque
WO2000039331A1 (fr) Polymorphisme nucleotidique unique dans un pyruvate deshydrogenase kinase isoenzyme 2 (pdk2) chez l'homme
JP2001149082A (ja) Ｃｄ３６変異遺伝子並びに脂質代謝異常により引き起こされる疾患の判定法および診断キット

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed